SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-23-001584
Filing Date
2023-08-08
Accepted
2023-08-08 09:03:07
Documents
74
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q tmb-20230630x10q.htm   iXBRL 10-Q 1553618
2 EX-31.1 tmb-20230630xex31d1.htm EX-31.1 13940
3 EX-32.1 tmb-20230630xex32d1.htm EX-32.1 6023
4 GRAPHIC tmb-20230630x10q001.jpg GRAPHIC 54482
  Complete submission text file 0001410578-23-001584.txt   7381821

Data Files

Seq Description Document Type Size
5 EX-101.SCH tmb-20230630.xsd EX-101.SCH 54013
6 EX-101.CAL tmb-20230630_cal.xml EX-101.CAL 64485
7 EX-101.DEF tmb-20230630_def.xml EX-101.DEF 225606
8 EX-101.LAB tmb-20230630_lab.xml EX-101.LAB 481667
9 EX-101.PRE tmb-20230630_pre.xml EX-101.PRE 364025
68 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20230630x10q_htm.xml XML 1248070
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

IRS No.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-12584 | Film No.: 231149550
SIC: 2834 Pharmaceutical Preparations